S
Scott H. Okuno
Researcher at Mayo Clinic
Publications - 167
Citations - 8890
Scott H. Okuno is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Sarcoma & Soft tissue sarcoma. The author has an hindex of 39, co-authored 167 publications receiving 7211 citations.
Papers
More filters
Journal ArticleDOI
A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group.
Charles G. Fisher,Christian P. DiPaola,Timothy C. Ryken,Mark H. Bilsky,Christopher I. Shaffrey,Sigurd Berven,James S. Harrop,Michael G. Fehlings,Stefano Boriani,Dean Chou,Meic H. Schmidt,David W. Polly,Roberto Biagini,Shane Burch,Mark B. Dekutoski,Aruna Ganju,Peter C. Gerszten,Ziya L. Gokaslan,Michael W. Groff,Norbert J. Liebsch,Ehud Mendel,Scott H. Okuno,Shreyaskumar Patel,Laurence D. Rhines,Peter S. Rose,Daniel M. Sciubba,Narayan Sundaresan,Katsuro Tomita,Péter Varga,Luiz Roberto Vialle,Frank D. Vrionis,Yoshiya Yamada,Daryl R. Fourney +32 more
TL;DR: The Spine Instability Neoplastic Score is a comprehensive classification system with content validity that can guide clinicians in identifying when patients with neoplastic disease of the spine may benefit from surgical consultation and aid surgeons in assessing the key components of spinal instability due to neoplasia.
Journal ArticleDOI
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein Abdul-Hassan Tawbi,Melissa Amber Burgess,Vanessa Bolejack,Brian A. Van Tine,Scott M. Schuetze,James C. Hu,Sandra P. D'Angelo,Steven Attia,Richard F. Riedel,Dennis A. Priebat,Sujana Movva,Lara E. Davis,Scott H. Okuno,Damon R. Reed,John Crowley,Lisa H. Butterfield,Ruth Salazar,Jaime Rodriguez-Canales,Alexander J. Lazar,Ignacio I. Wistuba,Laurence H. Baker,Robert G. Maki,Denise K. Reinke,Shreyaskumar Patel +23 more
TL;DR: The primary endpoint of overall response was not met, but pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and expansion to expanded cohorts of those subtypes is ongoing.
Journal ArticleDOI
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki,J. Kyle Wathen,Shreyaskumar Patel,Dennis A. Priebat,Scott H. Okuno,Brian L. Samuels,Michael P. Fanucchi,David C. Harmon,Scott M. Schuetze,Denise Reinke,Peter F. Thall,Robert S. Benjamin,Laurence H. Baker,Martee L. Hensley +13 more
TL;DR: Gem citabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma are found to have activity.
Journal ArticleDOI
Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group
Daryl R. Fourney,Evan Frangou,Timothy C. Ryken,Christian P. DiPaola,Christopher I. Shaffrey,Sigurd Berven,Mark H. Bilsky,James S. Harrop,Michael G. Fehlings,Stefano Boriani,Dean Chou,Meic H. Schmidt,David W. Polly,Roberto Biagini,Shane Burch,Mark B. Dekutoski,Aruna Ganju,Peter C. Gerszten,Ziya L. Gokaslan,Michael W. Groff,Norbert J. Liebsch,Ehud Mendel,Scott H. Okuno,Shreyaskumar Patel,Laurence D. Rhines,Peter S. Rose,Daniel M. Sciubba,Narayan Sundaresan,Katsuro Tomita,Péter Varga,Luiz Roberto Vialle,Frank D. Vrionis,Yoshiya Yamada,Charles G. Fisher +33 more
TL;DR: SINS demonstrated near-perfect inter- and intraobserver reliability in determining three clinically relevant categories of stability in patients with spinal tumor-related spinal instability.
Journal ArticleDOI
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
Burton L. Eisenberg,Jonathan Harris,Charles D. Blanke,George D. Demetri,Michael Heinrich,James C. Watson,John P. Hoffman,Scott H. Okuno,John M. Kane,Margaret von Mehren +9 more
TL;DR: There have been no prospective studies either evaluating the neoadjuvant use of IM in primary GIST or as a preoperative cytoreduction agent for metastatic GIST.